Sodium Sulfacetamide, Sulfur NDC 52187-531

NDC codes

FDA NDC Directory

Product NDC (as listed)52187-531Labeler and product segments. Claims need a package NDC.

Product NDC at billing width52187-0531Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
52187-531-16	52187053116	473 mL in 1 BOTTLE (52187-531-16)Marketed from May 20, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sodium Sulfacetamide, Sulfur
Generic name (nonproprietary): sodium sulfacetamide, sulfur
Active ingredients: Sulfur — 40 mg/mLSulfacetamide sodium — 80 mg/mL
Dosage form: Suspension
Route: Topical
Labeler: KMM Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: May 20, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Sulfonamides (Chemical structure)
Identifiers: Product ID 52187-531_a6185774-2622-4f52-e053-2995a90a42c0SPL ID a6185774-2622-4f52-e053-2995a90a42c0SPL set ID a6185774-2621-4f52-e053-2995a90a42c0RxCUI 1010234UNII 70FD1KFU70, 4NRT660KJQ
Pharmacologic class: Sulfonamide Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N452187053116 followed by a unit qualifier and the quantity

Package 52187-0531-16. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 20, 2020.

Indications (excerpt from the label)

INDICATIONS: This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)